In response to practice-changing data published within the past 5 years, an Expert Panel convened to update the guidelines and clinical practice considerations for the treatment of hormone receptor (HR)–positive and HR-negative/HER2-negative metastatic breast cancer.
The guideline recommends that patients with early-stage breast cancer who are younger than age 70 without significant competing comorbidities should undergo sentinel lymph node biopsy for axillary staging.
Pembrolizumab and chemotherapy improves overall survival compared with chemotherapy alone and represents a new standard of care for patients with treatment-naïve mTNBC whose tumors have a PD-L1 combined positive score of ≥ 10.
This site is intended for healthcare professionals in Europe and Japan only.
The selection of ASCO content on this site was made by the ASCO Publication and Education teams. Springer Healthcare selected the experts for interview. All content is made available solely for educational and informational purposes and personal use only.